🆕📝optimal cutoff points for severe AS vary by range of LVEF (<35%, 35%-50%, >50%) https://t.co/NCaVYsUxa8
🫀If LVEF <35%, use MG of 30 rather than 40 for severe AS
🫀MG & Vmax better than AVA in Dx severe AS adjudicated by C-CT
🫀In LG AS w LVEF <35%, DSE finds contractile reserve in 2/3 patients
🫀If LVEF 35-50%, DSE finds CR in 1/2 patients
🫀1/3 pts had paradoxical LG AS w LVEF >50% yet still got DSE(?)
🫀1/4 pts labeled pseudo-severe AS by DSE had true severe AS by C-CT(not validated in LF)
🔥 off the press! Brand new @ASE360 multimodality guideline. 👏 to chairs @WilliamZoghbi & Pei-Ni Jone MD et al.
Guidelines for the Evaluation of Prosthetic Valve Function With Cardiovascular Imaging: A Report From the American Society of Echocardiography https://t.co/ayjEdWgm6K
Hard to believe we have a full room discussing cardiac anti-amyloid therapy and endpoints in trials
@MathewMaurer opening with a brilliant talk as usual
Here is his summary of what's going on in silencers and stabilizers
#CardioTwitter
@anish_koka@drjohnm I agree with @AndrewFoy82 - you might get lucky and find a period of time that he can at least tolerate an aspirin and if he starts bleeding after the device you've left him at a bigger risk for a device-related thrombus. Sometimes doing nothing is the safest thing.
#TipsForNewDocs
When rounding with your attending, It's better to have the wrong plan than no plan. Having even the wrong plan= taking ownership for your patient. You'll learn from your mistakes and refine your clinical judgment.
#kittlesonrules
A local cardiologist at Delray Medical Center says he was watching the game and believes Hamlin was suffering from what is known as commotio cordis, CBS12's @Lenasalzbank reports.
https://t.co/O38kEkiohH
For this special episode of The Drive, we pulled together a variety of clips from previous podcasts about cardiovascular disease to help listeners better understand ASCVD, cholesterol, apoB, and more.
Listen here:
https://t.co/N8hGJ8WwI8
"We get to focus on the most wonderful organ and see it packaged differently with each patient we encounter."
@PatriceMcKay9 @DelrayMedCenter
#ILookLikeASonographer#MUAM#EchoFirst
Delighted to announce a
Clinical Trial Authorization (CTA) clearance
by UK MHRA (Medicines and Healthcare products Regulatory Agency)
for VERVE-101
as investigational Rx for patients with heterozygous familial hypercholesterolemia
https://t.co/tCIpNR4NbY
$VERV @VerveTx